

Applicants: Abraham Loyter, et al.
U.S. Serial No.: 10/511,990
Filed: as §371 national stage of
PCT/IL2003/000328, filed April 21, 2003
Page 2

Sequence Listing:

Please replace the Sequence Listing as filed in connection with the subject application with the substitute paper copy of the Sequence Listing attached hereto as **Exhibit C**.

EXHIBIT C

SEQUENCE LISTING

<110> Abraham Loyter
Adolf Graessman
Ahuva Nissim
Alexander Krichevsky
Nechama Zakai

<120> ANTI-NLS SCFV AND PEPTIDES AND USES THEREOF IN NUCLEAR IMPORT INHIBITION

<130> 73236/JPW/JW

<140> US 10/511,990
<141> 2004-10-21

<150> PCT/IL2003/000328
<151> 2003-04-21

<150> IL 149279
<151> 2002-04-22

<160> 16

<170> PatentIn version 3.3

<210> 1
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Random insert of CDR3 region from peptide library - Ab1 DNA

<400> 1
attagtagtg at 12

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3 random insert of Ab1

<400> 2

Ile Ser Ser Asp
1

<210> 3
<211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> CDR3 random insert of Ab2 DNA

<400> 3
gcttttatga agagtggtaa gcgttttatt cat

33

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3 random insert sequence of Ab2

<400> 4

Ala Phe Met Lys Ser Gly Lys Arg Phe Ile His
1 5 10

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR3 random insert sequence of Ab3 DNA

<400> 5
cattttcatt ataagggtaa gcttcagacg ttt

33

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3 random insert of Ab3

<400> 6

His Phe His Tyr Lys Gly Lys Leu Gln Thr Phe
1 5 10

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> SV40-NLS with extra C

<400> 7

Pro Lys Lys Lys Arg Lys Val Cys

1 5

<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> SV40-NLS-reverse with extra C

<400> 8

Cys Val Lys Arg Lys Lys Lys Pro Gly
1 5

<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> VprN with extra C

<400> 9

Cys Asn Glu Trp Thr Leu Glu Leu Leu Glu Lys Asn Glu Ala
1 5 10 15

Val Arg His Phe
20

<210> 10
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> VprC with extra C

<400> 10

Cys Arg His Ser Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn
1 5 10 15

Gly Ala Ser Arg Ser
20

<210> 11
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> VprN mutant with extra C

<400> 11

Cys Asn Glu Ala Thr Leu Glu Leu Leu Pro Glu Leu Lys Asn Pro Ala
1 5 10 15

Val Arg His Phe
20

<210> 12

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> ARM with extra C

<400> 12

Cys Gly Arg Lys Lys Arg Arg Gln Arg Arg Ala His Gln Asn
1 5 10 15

<210> 13

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Tat short NLS

<400> 13

Cys Gly Arg Lys Lys Arg
1 5

<210> 14

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> primer LMB3

<400> 14

cagggaaacag ctatgac

17

<210> 15

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer fdSEQ

<400> 15

gaattttctg tatgagg

17

<210> 16

<211> 20

<212> PRT

<213> bacteriophage fd

<400> 16

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln Ala
1 5 10 15

Ser Ala Thr Glu

20